CRISPR Therapeutics stock opened at $37.53 on Tuesday. CRISPR Therapeutics has a 52-week low of $30.04 and a 52-week high of $67.88. The firm’s fifty day moving average is $37.14 and its 200 day ...

--(BUSINESS WIRE)--#CRISPR--Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, presented data on two therapeutic applications ...

“We hope our technology will help people figure out which RNAs will be the biggest players for better therapeutics.” Currently, the researchers are using CRISPR-TO to move endogenous RNAs – RNA ...

“We hope our technology will help people figure out which RNAs will be the biggest players for better therapeutics.” Currently, the researchers are using CRISPR-TO to move endogenous RNAs ...

What sets CRISPR Therapeutics apart is the all-star team of founders, which includes Dr. Emmanuelle Charpentier, whose seminal research unveiled the key mechanisms of the CRISPR-Cas9 technology. It ...

The gene edit­ing com­pa­ny CRISPR Ther­a­peu­tics struck a deal worth $95 mil­lion up­front with Chi­na-based biotech Sir­ius Ther­a­peu­tics to joint­ly de­vel­op its ex­per­i ...

CRISPR Therapeutics CRSP announced that it has entered into a collaboration deal with San Diego-based privately held company, Sirius Therapeutics, for developing and commercializing novel siRNA ...

In his role as Scientific Advisor, Tony will help shape the Company's scientific strategy, identifying and advising on research and industry opportunities and raising awareness of Shift Bioscience's ...

CRISPR Therapeutics stock is down more than 80% from the peak it reached in 2021. The first drug from CRISPR Therapeutics launched early last year, but annualized sales are still less than $60 ...